Sign In
Buy FDMT
$10.18
+0.110 (+1.09%)
At Close: Jul 31, 2026
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
09:05pm, Tuesday, 23'rd Nov 2021 Intrado Digital Media
EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in a fireside chat at the Evercore ISI HealthCONx 2021 Conference. The fireside chat will take place on Thursday, December 2 nd , 2021 at 10:55 a.m. ET.
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down to $24.15
03:50pm, Friday, 19'th Nov 2021 Dakota Financial News
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) shares gapped down prior to trading on Friday . The stock had previously closed at $24.15, but opened at $22.79. 4D Molecular Therapeutics shares last traded at $22.79, with a volume of 612 shares changing hands. Separately, Zacks Investment Research raised 4D Molecular Therapeutics from a hold rating to a []
FDMT Stock: Why It Increased Today
03:37pm, Monday, 11'th Oct 2021
The stock price of 4D Molecular Therapeutics Inc (NASDAQ: FDMT) increased by over 13% during intraday trading today. This is why it happened.
EMERYVILLE, Calif., Oct. 10, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene thera
Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end
4D Molecular Therapeutics to Participate in Chardan's 5th Annual Genetic Medicines Conference
04:01pm, Wednesday, 29'th Sep 2021
EMERYVILLE, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ther
4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting
07:03am, Friday, 24'th Sep 2021
EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ther
New Strong Sell Stocks for July 23rd
10:44am, Friday, 23'rd Jul 2021
FDMT, BOOM, FRPT, GEL and HTBK have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2021.
EMERYVILLE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene thera
4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights
04:03pm, Thursday, 13'th May 2021
EMERYVILLE, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap
4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME
05:30pm, Wednesday, 12'th May 2021
EMERYVILLE, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap
4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference
07:05am, Friday, 30'th Apr 2021
EMERYVILLE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ther
- Abstracts on 4D-150 for wet AMD/DME and 4D-310 for Fabry disease accepted for oral presentations at ASGCT 24 th Annual Meeting
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights
04:02pm, Thursday, 25'th Mar 2021
- First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease
08:03am, Tuesday, 09'th Mar 2021
EMERYVILLE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: 4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ther
